Durante Destiny, Murugesh Venkatesh, Kalanquin Tyler, Gaisina Irina N, Rong Lijun, Moore Terry W
Department of Pharmaceutical Sciences, Retzky College of Pharmacy, University of Illinois Chicago IL 60612 USA
UICENTRE for Drug Discovery, University of Illinois Chicago IL 60612 USA.
RSC Med Chem. 2025 Aug 6. doi: 10.1039/d5md00533g.
Known for its widespread outbreaks, including the 2013-2016 epidemic that infected almost 29 000 individuals and resulted in approximately 11 300 deaths, Ebola virus (EBOV) and related filoviruses remain a current threat as consecutive filoviral outbreaks have occurred between 2021 through 2025. Due to high fatality rates of 40-90% among infected individuals, researchers have invested significant efforts to discover effective treatments for Ebola virus disease. Small molecules hold great potential for treating Ebola virus disease because they can target various stages of the filoviral life cycle, such as entry, transcription, replication, and egress; however, the FDA has not yet approved any small molecule treatments for EBOV. In this review, we report both historic and recent progress in the discovery of small molecule drugs for EBOV.
埃博拉病毒（EBOV）及其相关丝状病毒以广泛爆发而闻名，包括2013 - 2016年的疫情，感染了近29000人，导致约11300人死亡。由于在2021年至2025年期间连续发生丝状病毒爆发，埃博拉病毒及其相关丝状病毒仍然是当前的一大威胁。由于感染者的死亡率高达40% - 90%，研究人员投入了大量精力来寻找治疗埃博拉病毒病的有效方法。小分子药物在治疗埃博拉病毒病方面具有巨大潜力，因为它们可以针对丝状病毒生命周期的各个阶段，如进入、转录、复制和释放；然而，美国食品药品监督管理局（FDA）尚未批准任何用于治疗埃博拉病毒的小分子药物。在本综述中，我们报告了在发现用于治疗埃博拉病毒的小分子药物方面的历史和最新进展。
